354 related articles for article (PubMed ID: 34093863)
41. CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach.
Zhang X; Hu Q; He X; Cui X; Liang Z; Wang L; Deng X; Zhang Z; Sheng W; Han XD
J Nanobiotechnology; 2023 May; 21(1):159. PubMed ID: 37208748
[TBL] [Abstract][Full Text] [Related]
42. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
43. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
[TBL] [Abstract][Full Text] [Related]
44. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
45. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
Furumoto K; Soares L; Engleman EG; Merad M
J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
[TBL] [Abstract][Full Text] [Related]
46. Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.
West EJ; Scott KJ; Jennings VA; Melcher AA
Br J Cancer; 2011 Sep; 105(6):787-95. PubMed ID: 21847125
[TBL] [Abstract][Full Text] [Related]
47. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
48. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence.
Gong S; Liang X; Zhang M; Li L; He T; Yuan Y; Li X; Liu F; Yang X; Shen M; Wu Q; Gong C
Small; 2022 Dec; 18(50):e2107061. PubMed ID: 36323618
[TBL] [Abstract][Full Text] [Related]
49. Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8
Darling R; Senapati S; Christiansen J; Liu L; Ramer-Tait AE; Narasimhan B; Wannemuehler M
Int J Nanomedicine; 2020; 15():6579-6592. PubMed ID: 32982219
[TBL] [Abstract][Full Text] [Related]
50. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
51. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
[TBL] [Abstract][Full Text] [Related]
52. Dendritic cell-based immunotherapy: a basic review and recent advances.
Constantino J; Gomes C; Falcão A; Neves BM; Cruz MT
Immunol Res; 2017 Aug; 65(4):798-810. PubMed ID: 28660480
[TBL] [Abstract][Full Text] [Related]
53. Chitosan gel vaccine protects against tumour growth in an intracaecal mouse model of cancer by modulating systemic immune responses.
Highton AJ; Girardin A; Bell GM; Hook SM; Kemp RA
BMC Immunol; 2016 Oct; 17(1):39. PubMed ID: 27756214
[TBL] [Abstract][Full Text] [Related]
54. BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma.
Kremenovic M; Chan AA; Feng B; Bäriswyl L; Robatel S; Gruber T; Tang L; Lee DJ; Schenk M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732347
[TBL] [Abstract][Full Text] [Related]
55. Natural CD8⁺25⁺ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma.
Xie Y; Zhang X; Zhao T; Li W; Xiang J
Biochem Biophys Res Commun; 2013 Aug; 438(1):152-5. PubMed ID: 23876314
[TBL] [Abstract][Full Text] [Related]
56. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
Bulgarelli J; Tazzari M; Granato AM; Ridolfi L; Maiocchi S; de Rosa F; Petrini M; Pancisi E; Gentili G; Vergani B; Piccinini F; Carbonaro A; Leone BE; Foschi G; Ancarani V; Framarini M; Guidoboni M
Front Immunol; 2019; 10():2353. PubMed ID: 31649669
[TBL] [Abstract][Full Text] [Related]
57. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
58. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
59. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
[TBL] [Abstract][Full Text] [Related]
60. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
